Pemetrexed in Patients With Advanced Neuroendocrine Tumors

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out what effects (good and bad) pemetrexed has on patients with advanced neuroendocrine tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital
• Treatments: Pemetrexed

Criteria

Inclusion Criteria:

• Metastatic or locally unresectable neuroendocrine tumor, excluding small cell carcinoma

• Measurable tumor

• 18 year of age or older

• ECOG performance status of 0,1 or 2

• Life expectancy of greater than 12 weeks

• WBC: > 3.0/mm3

• Plts: > 100,000/mm3

• Bilirubin: < 2.0 mg/dl

• AST < 3 x ULN (except in patients with known hepatic metastases wherein SST may be < 5 x ULN)

• Neutrophils > 1000/mm3

• Creatinine Clearance > 45 ml/min. Should be measured using the standard Cockroft-Gault formula

Exclusion Criteria:

• Prior treatment with pemetrexed

• Clinically apparent central nervous system metastases or carcinomatous meningitis

• Myocardial infarction in the past 6 months

• Major surgery in the past two weeks

• Uncontrolled serious medical or psychiatric illness

• Pregnant or lactating women